- Home
- AGIO vs INVA Comparison
AGIO vs INVA Comparison
Compare AGIO & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | INVA |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AGIO | INVA |
|---|---|---|
| Price | $32.48 | $20.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $46.25 | $35.00 |
| AVG Volume (30 Days) | 686.1K | ★ 733.2K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 1.25 |
| Revenue | $43,011,000.00 | ★ $217,217,000.00 |
| Revenue This Year | $237.78 | $9.72 |
| Revenue Next Year | $92.30 | $8.58 |
| P/E Ratio | ★ N/A | $16.88 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $22.24 | $16.52 |
| 52 Week High | $46.00 | $25.15 |
Technical Indicators
Market Signals| Indicator | AGIO | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 50.35 |
| Support Level | $32.17 | $20.39 |
| Resistance Level | $35.77 | $21.73 |
| Average True Range (ATR) | 1.18 | 0.47 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 51.25 | 66.39 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.